doi: 10.3389/fnut.2025.1615671 Received 21 April 2025 Accepted 29 July 2025 Published 13 August 2025 Volume 12 - 2025 Edited by Ismael San Mauro Martn, CINUSA Group, Spain Reviewed by Simone Birgit Bayer, University of Otago, Christchurch, New Zealand Emanuela Ribichini, Sapienza University of Rome, Italy Aleksandar Sic, Advocate Illinois Masonic Medical Center, United States Updates Copyright 2025 Khan, Brnstad, Hillestad, Steinsvik, Hausken, Berentsen and Lied
What is CJC-1295 and how does it work
This genetic insight helps your provider select semaglutide, tirzepatide, or even dual-compound protocols like GLP-Squared to maximize your weight-loss potential
These individualized decisions are difficult to make without close provider engagement, which reinforces the value proposition of IVIM ongoing monitoring model even after the active weight loss phase has concluded
Some patients experience mild redness, warmth, or slight tenderness at the injection site within hours of administration
This study was (partially) supported by the Italian Ministry of Health (Ricerca Corrente 2024)
